← All trials
NCT04974528
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2021
- Primary completion
- Apr 30, 2023
- Completion date
- Apr 30, 2024
- First posted
- Jul 23, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MannKind CorpLead sponsor
- MannKind CorpStudy director
- Jaeb Center for Health ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.